Day September 27, 2021

Civil Society Letter to President Biden: TRIPS Waiver Must Apply to All Intellectual Property Rights, Not Just Patents

[Letter endorsed by 12 civil society groups] The Administration has displayed great leadership by announcing support for a TRIPs waiver and attempting to fashion an approach agreeable to all parties. As it continues these efforts, it should resist the temptation to narrow the scope of the waiver to exclude copyrights and other rights. Ambassador Tai’s May 5 announcement expressed support for waiving “intellectual property protections,” not just patent protections. We urge the Administration to remain steadfast in its advocacy for including all forms of intellectual property within the scope of the waiver.

Strong Intellectual Property Protection, Weak Competition Rules – or the Other Way Around to Accelerate Technology Transfer to the Global South?

[Klaus Beiter] Competition law provisions relating to intellectual property (IP) rights should play an enhanced role in facilitating the domestic and international transfer and dissemination of technology. IP-related competition rules in the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) create an obligation for Member States to apply competition law in the IP context. TRIPS competition rules should be read in a “prodevelopment” fashion – IP rights need to be read reductively, IP-related competition law expansively. Ten considerations for a “prodevelopment” IP-related competition law are formulated.

Open Letter to Presidents of Latin America and the Caribbean: COVID-19 Vaccine Access

[Civil society letter endorsed by 81 organizations and individuals] ...Vaccine production has been insufficient to vaccinate the entire world population, therefore we consider that it is necessary to restructure the acquisition and production models to improve the availability of doses at the most favorable price for our region, which at the same time is going through a serious economic crisis. Therefore, it is imperative that pharmaceutical companies share technology and knowledge with other qualified producers as soon as possible and it is important that the countries of the region take a firm position towards the industry.

Introducing the Copyright Anxiety Scale

[Amanda Wakaruk, Céline Gareau-Brennan and Matthew Pietrosanu] Abstract: Navigating copyright issues can be frustrating to the point of causing anxiety, potentially discouraging or inhibiting legitimate uses of copyright-protected materials. A lack of data about the extent and impact of these phenomena, known as copyright anxiety and copyright chill, respectively, motivated the authors to create the Copyright Anxiety Scale (CAS). This article provides an overview of the CAS’s development and validity testing. Results of an initial survey deployment drawing from a broad cross-section of respondents living in Canada and the United States (n = 521) establishes that the phenomenon of copyright anxiety is prevalent and likely associated with copyright chill.